SecBot SecBot
SECBOTREPLAY Home › Report › CGON

CGON · James Mule, a director at CG Oncology, filed a Form 144 to notify…

CG Oncology, Inc. · 144 filed Apr 17, 2026 at 16:34 ET

At the news

NEUTRALIMPACT 3/10

144 filed Apr 17, 2026 at 16:34 ET

James Mule, a director at CG Oncology, filed a Form 144 to notify intent to sell up to 17,564 shares of common stock, received through the exercise of stock options. The filing indicates planned sales under a 10b5-1 plan, with option exercises occurring as early as March 2026.

  • James Mule, director of CG Oncology, intends to sell 17,564 shares of common stock
  • Shares were or will be acquired through exercise of stock options between March 2026 and June 2025
  • Sales are being conducted under a 10b5-1 plan, indicating prearranged trading strategy
  • Total value of shares to be sold is approximately $116,514 based on current market price

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access